Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595748 | 0.86 | GSK3B (0.40) | RAB9AMAPTDEGS1ABCC9ABCC8 | |
| SCHEMBL18839350 | 0.83 | HCAR3 (0.37) | — | |
| SCHEMBL15173481 | 0.82 | CYP1A2 (0.33) | CYP1A2L3MBTL1PIK3CG | |
| SCHEMBL1016475 | 0.79 | SMN1; SMN2 (0.45) | CYP1A2KMT2ARAB9AMAPTKDM4E | |
| SCHEMBL2067637 | 0.78 | CCNT1 (0.38) | MAPTKDM4EL3MBTL1 | |
| SCHEMBL2418477 | 0.77 | PTK2 (0.59) | PTK2CYP1A2GAAKMT2ANSD2 | |
| SCHEMBL14660182 | 0.76 | PIP5K1C (0.34) | CYP1A2RAB9AMAPTKDM4EL3MBTL1 | |
| SCHEMBL290041 | 0.76 | — | — | |
| SCHEMBL532324 | 0.76 | KMT2A (0.36) | KMT2A | |
| SCHEMBL395314 | 0.75 | KDM4E (0.36) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695248-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213663-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-8283360-B2 | Bicyclic heterocyclic derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| WO-2012112962-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112966-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112963-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | SCHERING PLOUGH CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2379564-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011103430-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010071819-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | PTK2 2054/4885CYP1A2 395/4885GAA 4326/4885 |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | GPR119, GID4, TLR4 | PTK2 2606/4885CYP1A2 281/4885GAA 248/4885 |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | PTK2 2771/4885CYP1A2 761/4885GAA 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.